{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:50:01Z","timestamp":1762249801226,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.thromres.2025.109453","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:59:52Z","timestamp":1756915192000},"page":"109453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The influence of metastasis on clinical outcomes in patients with cancer-associated isolated distal deep vein thrombosis: A pre-specified subgroup analysis from the ONCO DVT study"],"prefix":"10.1016","volume":"254","author":[{"given":"Michihisa","family":"Umetsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugo","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Ogihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Otsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sueta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Tsubata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Shikama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Hosoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuki","family":"Chatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kitae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daijirou","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukashi","family":"Serizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2025.109453_bb0005","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cncr.25714","article-title":"Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2025.109453_bb0010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"Journal of thrombosis and haemostasis: JTH."},{"key":"10.1016\/j.thromres.2025.109453_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2016.06.033","article-title":"Epidemiology of venous thromboembolism in the Framingham heart study","volume":"145","author":"Puurunen","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2025.109453_bb0020","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1253\/circj.CJ-19-0515","article-title":"Cancer-associated venous thromboembolism in the real world - from the COMMAND VTE registry","volume":"83","author":"Sakamoto","year":"2019","journal-title":"Circ. J."},{"key":"10.1016\/j.thromres.2025.109453_bb0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2023.12.016","article-title":"Cancer-associated venous thromboembolism in the direct oral anticoagulants era: insight from the COMMAND VTE Registry-2","volume":"234","author":"Chatani","year":"2024","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2025.109453_bb0030","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of Cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109453_bb0035","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral factor Xa inhibitor with low molecular weight heparin in patients with Cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2025.109453_bb0040","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109453_bb0045","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1161\/CIRCULATIONAHA.123.066360","article-title":"Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis (ONCO DVT study): an open-label, multicenter, randomized clinical trial","volume":"148","author":"Yamashita","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2025.109453_bb0050","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"Jama"},{"key":"10.1016\/j.thromres.2025.109453_bb0055","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"Journal of thrombosis and haemostasis: JTH."},{"key":"10.1016\/j.thromres.2025.109453_bb0060","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1253\/circj.CJ-13-0886","article-title":"Current venous thromboembolism management and outcomes in Japan","volume":"78","author":"Nakamura","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.thromres.2025.109453_bb0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejim.2023.08.007","article-title":"Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants","volume":"118","author":"Kaneda","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.thromres.2025.109453_bb0070","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109453_bb0075","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/jjco\/hyaa112","article-title":"Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE registry","volume":"50","author":"Ohashi","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2025.109453_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100739","article-title":"Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study","volume":"34","author":"S\u00f8rensen","year":"2023","journal-title":"The Lancet regional health Europe."},{"key":"10.1016\/j.thromres.2025.109453_bb0085","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109453_bb0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.thromres.2019.11.007","article-title":"Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study","volume":"185","author":"Mulder","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2025.109453_bb0095","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1111\/jth.15461","article-title":"Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study","volume":"19","author":"Giustozzi","year":"2021","journal-title":"Journal of thrombosis and haemostasis: JTH."},{"key":"10.1016\/j.thromres.2025.109453_bb0100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.01.023","article-title":"Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study","volume":"165","author":"Verso","year":"2022","journal-title":"European Journal of cancer (Oxford, England: 1990)."},{"key":"10.1016\/j.thromres.2025.109453_bb0105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs Dalteparin in Cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2025.109453_bb0110","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study","volume":"13","author":"Francis","year":"2015","journal-title":"Journal of thrombosis and haemostasis: JTH."},{"key":"10.1016\/j.thromres.2025.109453_bb0115","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/jth.14561","article-title":"Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study","volume":"17","author":"Di Nisio","year":"2019","journal-title":"Journal of thrombosis and haemostasis: JTH."},{"key":"10.1016\/j.thromres.2025.109453_bb0120","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2025.109453_bb0125","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2025.109453_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor\u2019s choice - European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the Management of Venous Thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.thromres.2025.109453_bb0135","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2025.109453_bb0140","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1253\/circj.CJ-20-0223","article-title":"Risk factors for major bleeding during anticoagulation therapy in Cancer-associated venous thromboembolism - from the COMMAND VTE registry","volume":"84","author":"Nishimoto","year":"2020","journal-title":"Circ. J."},{"key":"10.1016\/j.thromres.2025.109453_bb0145","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1007\/s00520-021-06139-3","article-title":"Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy","volume":"29","author":"Guven","year":"2021","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer."},{"key":"10.1016\/j.thromres.2025.109453_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.06.029","article-title":"Extended anticoagulation therapy on clinical outcomes in patients with gastrointestinal cancer and isolated distal deep vein thrombosis: insights from the ONCO DVT study","author":"Yamashita","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.thromres.2025.109453_bb0155","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose Apixaban for Cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:39:05Z","timestamp":1762249145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825002038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":31,"alternative-id":["S0049384825002038"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109453","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The influence of metastasis on clinical outcomes in patients with cancer-associated isolated distal deep vein thrombosis: A pre-specified subgroup analysis from the ONCO DVT study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109453"}}